Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Phase 3 trial of elafibranor in PBC with inadequate response or intolerance to UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elafibranor received accelerated approval in 2024 as a second-line therapy for adults with PBC who have an inadequate response or intolerance to UDCA, based on results from the phase 3 ELATIVE trial demonstrating significant biochemical response and favorable tolerability, including no worsening of pruritus [50,51].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“On the other hand, seladelpar (PPAR-δ selective) consistently improves pruritus and shows high biochemical response rates, while elafibranor (dual PPAR-α/δ) improves biochemical endpoints with a neutral pruritus effect but a reassuring safety signal overall [16,50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Among patients with moderate-to-severe pruritus (44 in the elafibranor group and 22 in the placebo group), the least-squares mean change in WI-NRS score from baseline through week 52 did not differ significantly between the two groups.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“However, fibrosis-related endpoints such as transient elastography and non-invasive fibrosis scores were neutral in this trial.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Normalization of ALP levels at week 52 occurred in 15% of patients receiving elafibranor and in none of the patients receiving placebo (p < 0.002) [50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citation
Cited by
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hirschfield, G. M., Bowlus, C. L., Mayo, M. J., Kremer, A. E., Vierling, J. M., Kowdley, K. V., Levy, C., Villamil, A., Ladrón de Guevara Cetina, A. L., Janczewska, E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312100 · Cited by 286
Self-citationTanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
Self-citationFerraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.013 · Cited by 192
Trivedi, P. J., Hirschfield, G. M., Adams, D., & Vierling, J. M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.049 · Cited by 112
Self-citationAltered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 103
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Yan, M., Cui, Y., & Xiang, Q. (2025) · Theranostics · doi:10.7150/thno.106597 · Cited by 95
Kowdley, K. V., Hirschfield, G. M., Coombs, C., Malecha, E. S., Bessonova, L., Li, J., Rathnayaka, N. S., Mells, G. F., Jones, D. E., Trivedi, P. J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003029 · Cited by 80
Self-citationAssessment of fatigue and its impact in chronic liver disease
Younossi, Z. M., Kremer, A. E., Swain, M. G., Jones, D. E., Bowlus, C. L., Trauner, M., Henry, L. L., & Gerber, L. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.008 · Cited by 63
Self-citationPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 81
Self-citationThe history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 46
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Lipid metabolism in homeostasis and disease
Li, Z., Deng, W., Yang, L., Tang, C., Yue, J.-M., Monteiro, O., Baptista‐Hon, D. T., & Li, T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02357-x · Cited by 74
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000864 · Cited by 38
“…this indication, [17] with fenofibrate replacing it in some jurisdictions [18] ), the experimental approach of the combination of OCA and bezafibrate, [19] and the alternative PPAR agonists with different subtype specificity (elafibranor and seladelpar [20,21] ) currently in clinical development.”
BackgroundInfluentialSelf-citationNovel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
Topouzis, S., Papapetropoulos, A., Alexander, S. P. H., Cortese-Krott, M. M., Kendall, D. A., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.17458 · Cited by 43
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
Primary biliary cholangitis: Personalizing second-line therapies
Levy, C., & Bowlus, C. L. (2024) · Hepatology · doi:10.1097/hep.0000000000001166 · Cited by 44
Self-citationPolypharmacology: new drugs in 2023–2024
Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00715-8 · Cited by 45
Gupta, V., Sehrawat, T. S., Pinzani, M., & Strazzabosco, M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.07.044 · Cited by 43
PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 35
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Levy, C., Abouda, G. F., Bilir, B. M., Bonder, A., Bowlus, C. L., Campos‐Varela, I., Cazzagon, N., Chandok, N., Cheent, K. S., Cortez‐Pinto, H., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.025 · Cited by 37
Self-citationTrauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 32
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 31
Lin, W., Wang, J.-X., & Liu, Y.-J. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02460-0 · Cited by 28
Blair, H. A. (2024) · Drugs · doi:10.1007/s40265-024-02075-8 · Cited by 27
Drug‐Induced Liver Injury in Patients With Chronic Liver Disease
Ghabril, M., Vuppalanchi, R., & Chalasani, N. (2025) · Liver International · doi:10.1111/liv.70019 · Cited by 30
Bile acids and their receptors in hepatic immunity
Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 31
Koizumi, A., Kaji, K., Nishimura, N., Asada, S., Matsuda, T., Tanaka, M., Yorioka, N., Tsuji, Y., Kitagawa, K., Sato, S., et al. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i28.3428 · Cited by 28
Intrahepatic cholestasis of pregnancy
Dajti, E., Tripodi, V. P., Hu, Y., Estiú, M. C., Shan, D., Mazzella, G., & Azzaroli, F. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00633-2 · Cited by 36
Juanola, O., Francés, R., & Caparrós, E. (2024) · Visceral Medicine · doi:10.1159/000535962 · Cited by 26
Guo, Z., He, K., Pang, K., Yang, D., Lyu, C., Xu, H., & Wu, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084321 · Cited by 31
Dong, L., Lou, W., Xu, C., & Wang, J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03228-x · Cited by 30
PPAR Agonists in Primary Biliary Cholangitis
Schnabl, B. (2024) · New England Journal of Medicine · doi:10.1056/nejme2313802 · Cited by 22
Antwi, M. B., Jennings, A., Lefere, S., Clarisse, D., Geerts, A. M., Devisscher, L., & Bosscher, K. D. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00013-6 · Cited by 27
Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis
Tan, J. J.-R., Chung, A. H.-L., Loo, J. H., Quek, J. W. E., Sharma, S., Singh, C. L., Yap, R. X. J., Tay, W. X., Smith, M. K., Lytvyak, E., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.03.025 · Cited by 42
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 26
Levy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003603 · Cited by 20
Self-citationDrugs targeting peroxisome proliferator-activated receptors
Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 25
Nielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 22
An, J., Chon, Y. E., Kim, G., Kim, M. N., Kim, H. Y., Lee, H. A., Yu, J. H., Choi, M., Jun, D. W., Kim, S. U., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0586 · Cited by 24
Giannini, E. G., Pasta, A., Calabrese, F., Labanca, S., Marenco, S., Pieri, G., Torres, M. C. P., & Strazzabosco, M. (2024) · Liver International · doi:10.1111/liv.16222 · Cited by 21
Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease
Dubois, V., Lefèbvre, P., Staels, B., & Eeckhoute, J. (2024) · Gut · doi:10.1136/gutjnl-2023-331741 · Cited by 18
Lytvyak, E., Hirschfield, G. M., Shreekumar, D., Wong, Y. J., & Montaño‐Loza, A. J. (2025) · Liver International · doi:10.1111/liv.70190 · Cited by 21
Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Zhu, C.-Y., Yu, P., Sun, Q., Hong, D., Yang, C., & Naranmandura, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107862 · Cited by 19
Primary biliary cholangitis and the narrowing gap towards optimal disease control
Cançado, G. G. L., Lleò, A., Levy, C., Trauner, M., & Hirschfield, G. M. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00025-1 · Cited by 24
Self-citationGóméz, E., Montero, J. L., Molina, E., García-Buey, L., Casado, M., Fuentes, J., Simón, M. Á., Díaz‐González, Á., Jorquera, F., Morillas, R. M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18004 · Cited by 15
Carbone, M., Gerussi, A., Cardinale, V., Cazzagon, N., Cossiga, V., Lleò, A., Marrone, G., Marzioni, M., Moschetta, A., Muratori, L., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.05.002 · Cited by 18
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 19
Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 15
Filippis, B. D., Granese, A., & Ammazzalorso, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2332661 · Cited by 14
Peroxisome proliferator–activated receptor delta and liver diseases
Yamazaki, T., Cable, E. E., & Schnabl, B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000646 · Cited by 16
Wiegand, J., Franke, A., Müller, T., Stein, K., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., Naumann, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2382-7720 · Cited by 12
Self-citationPirola, L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i4.99312 · Cited by 12
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14
Hove, J. L. K. V., Friederich, M. W., Hock, D. H., Stroud, D. A., Caruana, N. J., Christians, U., Schniedewind, B., Michel, C. R., Reisdorph, R. M., Gonzalez, E. D. J. L., et al. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101905 · Cited by 13
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
Vincentis, A. D., Ampuero, J., Terracciani, F., D’Amato, D., Gerussi, A., Cristoferi, L., Cazzagon, N., Bonaiuto, E., Floreani, A., Calvaruso, V., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.008 · Cited by 13
Self-citationFreer, A., Williams, F. R., Durman, S., Hayden, J. K., Armstrong, M. J., & Trivedi, P. J. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101210 · Cited by 24
The treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 16
Zhang, J., Liu, X., Jin, X. J., Mao, X., Xu, X., Zhang, X., Shang, K., Xu, Y., Zhang, Y., Meng, G., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107664 · Cited by 11
Kowdley, K. V., Victor, D. W., MacEwan, J. P., Nair, R., Levine, A., Hernandez, J., Bessonova, L., Li, J., Wheeler, D., & Hirschfield, G. M. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70120 · Cited by 19
Self-citationBarrio, M. D., Díaz‐González, Á., & Alonso‐Peña, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167905 · Cited by 14
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 18
Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments
Gabrielli, F., Crepaldi, E., Cavicchioli, A., Rivi, M., Costanzo, A. A. C., Cursaro, C., & Andreoné, P. (2024) · Biomolecules · doi:10.3390/biom14101227 · Cited by 12
Self-citationPPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old
Tanaka, A., & Corpechot, C. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102358 · Cited by 9
Self-citationVuppalanchi, R., Cruz, M. M., Momin, T., Shaikh, F., Swint, K., Patel, H., & Parmar, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3450 · Cited by 10
Unmet needs in autoimmune liver diseases
Kolev, M., Kremer, A. E., Sokollik, C., Gershwin, M. E., Beretta‐Piccoli, B. T., Andrade, R. J., Bobzin, C., de Boer, Y. S., de Martin, E., Deganello, A., et al. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102565 · Cited by 12
Self-citationKoc, O. M., Toussaint, A. C., Untas, A., Milkiewicz, P., Ytting, H., Buck, L., Jones, D. E., Hirschfield, G. M., Leburgue, A., Schramm, C., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00257-2 · Cited by 19
Self-citationZhang, H., Dong, X., Zhu, L., & Tang, F. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i40.4393 · Cited by 12
Sierra, L., Ferrigno, B. W., Marenco‐Flores, A., Alsaqa, M., Rojas, N., Barba, R., Goyes, D., Medina‐Morales, E., Saberi, B., Patwardhan, V. R., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101945 · Cited by 12
Cholestatic liver diseases: modern therapeutics
McNally, B. B., & Carey, E. J. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2473490 · Cited by 11
The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine
Men, X., Liu, Y., Zhao, H., Xie, B., Guo, C., Leung, P. S. C., Timilsina, S., Gershwin, M. E., Shang, Y., & Han, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09074-x · Cited by 15
Advancing Second-Line Treatment for Primary Biliary Cholangitis
Assis, D. N. (2024) · New England Journal of Medicine · doi:10.1056/nejme2312745 · Cited by 8
The role of PPAR in fungal keratitis
Zhou, H., Zhang, H., Bi, M., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454463 · Cited by 10
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
Aksoyalp, Z. Ş., Kayki‐Mutlu, G., Wojnowski, L., & Michel, M. C. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04020-2 · Cited by 11
Gelhorn, H. L., Currie, B. M., Bushnell, D. M., Martin, M. L., Fofana, F., Karn, H., Mayo, M. J., Jones, D. E., McLaughlin, M., & von Maltzahn, R. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03798-x · Cited by 12
Self-citationKhan, M. N., Ahmed, K., Siddiqui, L., Baig, H., Kahfi, J., Emwas, A.-H. M., Jaremko, M., & Saleem, R. S. Z. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142526 · Cited by 11
Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies
Kode, V., & Yimam, K. K. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00638-7 · Cited by 11
Evolving therapeutic landscape of primary biliary cholangitis: A review
Mitchell, N. E., Chan, S., Diaz, D. J., Ansari, N., Lee, J. S., & Twohig, P. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107223 · Cited by 11
Ye, K., Yao, X., Lu, D., Tan, C., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1620073 · Cited by 7
Ali, J. S., Ali, T. S., & Hasibuzzaman, M. A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002868 · Cited by 9
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis
Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7
Tana, M. M.-S., & Hirschfield, G. M. (2025) · JAMA · doi:10.1001/jama.2025.20067 · Cited by 11
Abbas, N., Smith, R. A., Lytvyak, E., Scraravaglio, M., Halliday, N., Almahroos, A., Eden, N., Lloyd‐Madden, D., Sharma, S., Ferguson, J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70378 · Cited by 9
Self-citationAdvancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies
Curto, A., Iamello, R. G., Lynch, E. N., & Galli, A. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i30.109028 · Cited by 6
de Abreu, E. S., Fernandes, G. P., Lacerda, H., Reginato, P. H., Neves, H. A. F., Gonzalez, C. D. S., Eaton, J. E., & Cançado, G. G. L. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70094 · Cited by 9
Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults
Brown, C. L., & Bajaj, J. S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003641.07 · Cited by 10
Kowdley, K. V., Ieyoub, J., Pan, Y., Samnaliev, M., Ito, D., & Perez, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70391 · Cited by 9
Self-citationMartins, A., Khakoo, N. S., Reddy, A., Reynolds, J. M., Corpechot, C., Rousseau, A., Murad, M., Sultan, S., & Levy, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001465 · Cited by 12
Self-citationDong, L., Lou, W., & Wang, J. (2025) · Food Research International · doi:10.1016/j.foodres.2025.115816 · Cited by 6
de Abreu, E. S., Reginato, P. H., Pitanga, J. F. J., Borges, P. N., Soret, P., Corpechot, C., & Cançado, G. G. L. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09044-5 · Cited by 6
Self-citationRevisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis
Chen, Y., Zheng, K., Da, G., Wang, X., Wei, Y., Wang, G., Zhang, F., & Wang, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406268 · Cited by 7
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
Bai, Y., Li, R., Zhang, X., Seng, D., Xu, Y., Zhang, S., & Yuan, S. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2704735 · Cited by 6
Primary biliary cholangitis. Treatment options in 2025. A narrative review
Angelara, M., Papachristou, K., Papatheodoridi, Μ., Ansari, N. N., Karagiannakis, D. S., & Ανδρουτσάκος, Θ. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1698833 · Cited by 8
Bezafibrate for primary biliary cholangitis: time to act on the evidence
Corpechot, C., Londoño, M., Villamil, A., Ytting, H., Tanaka, A., & Beuers, U. H. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01135-y · Cited by 8
Self-citationJamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102335 · Cited by 6
Levy, C., Jones, D. E. J., Mayo, M. J., Bowlus, C. L., Kowdley, K. V., Hirschfield, G. M., Liu, J., Burk, C., Carroll, S., Crittenden, D. B., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70630 · Cited by 7
Self-citation
Metadata
- Authors
- Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., Vierling, J. M., Villamil, A., Addy, C., Dietrich, J., Germain, J.-M., Mazain, S., Rafailovic, D., Taddé, B., Miller, B., Shu, J., Zein, C. O., & Schattenberg, J. M.
- Affiliations
- Universidade Federal do Rio Grande (BR)
- From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); Schiff Center for Liver Diseases, University of Miami, Miami (C.L.); the Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Turkey (U.S.A.); Gastroenterology and Hepatology Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (M.R.A.-S.); Medicina Interna Metabolica, Baggiovara Hospital, Azienda Ospedaliero-Universitaria di Modena and Università di Modena e Reggio Emilia, Modena (P.A.), and the Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, and the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza (P.I.) — all in Italy; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago ...
- ORCID
- Kowdley, Kris V.
- Bowlus, Christopher L.
- Levy, Cynthia
- Akarca, Ulus S.
- Arrese, Marco
- Corpechot, Christophe
- Francque, Sven M.
- Heneghan, Michael A.
- Invernizzi, Pietro
- Jones, David
- Lawitz, Eric
- Mayo, Marlyn J.
- Shiffman, Mitchell L.
- Swain, Mark G.
- Vierling, John M.
- Villamil, Alejandra
- Addy, Carol
- Dietrich, Julie
- Rafailovic, Dragutin
- Schattenberg, Jörn M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 795-805
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388621682
- Semantic Scholar
- 737ff94dc0523a82fdfc3a80f921364b42703d37
- Cited by
- 314
- References
- 33
- Citations by year
- 2026: 112 · 2025: 125 · 2024: 76
- FWCI
- 52.53
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Ipsen
- GENFIT
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- elafibranor, primary biliary cirrhosis, ursodeoxycholic acid, cholestasis, alkaline phosphatase, pruritus, liver fibrosis, treatment efficacy, drug safety, bile duct destruction, cholestatic liver disease
- MeSH terms
- Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Cholestasis, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Propionates, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, Chalcones, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.